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Background
ANRS HIV-LIPO-5 vaccine includes 5 long peptides,
Gag17–35, 253–284, Pol325–355, Nef66–97 and 116–
145, containing multiple CD8+ and CD4+ T-cell epitopes,
coupled to a palmytoil tail. Phase 1 studies have shown
that vaccine dosage at 500 μg/lipopeptide elicits cellular
immune responses. Whether HIV-LIPO5 immunogenicity
varies with the dosage is unknown.
Methods
One hundred and thirty two 21- to 55-year-old HIV nega-
tive volunteers, enrolled in 6 HIV-vaccine clinical sites,
were randomized to receive either the HIV-LIPO-5 vaccine
at 50 μg/lipopeptide (N = 32; LIPO-5 50), 150 μg (N = 32;
LIPO-5 150), 500 μg (N = 33; LIPO-5 500) or placebo (N
= 34). Vaccinations were given IM at weeks 0, 4, 12 and
24. HIV-1 specific CD8+ (IFN-gamma ELISpot on PBMC
cultured 12-days) and CD4+ responses (PBMC lympho-
proliferation) were assessed at baseline, two weeks after
each injection, and at week 48.
Results
No adverse events attributable to vaccine were noted
throughout the study. Local reactions appeared dose-
dependent; no differences in systemic reactions were
observed between groups. Sustained (at least on 2 sepa-
rate occasions) CD8+ response rates to at least one HIV-1
pool were: 5/32 (16%) for placebo, 22/32 (69%) for
LIPO-5 50, 21/33 (64%) for LIPO-5 150 and 21/34 (62%)
for LIPO-5 500 groups (P ≤ .0001 for all comparisons to
placebo). Cumulative CD4+ response rates were: placebo:
2/32 (6%), LIPO-5 50: 15/32 (47%), LIPO-5 150: 18/33
(55%) and LIPO-5 500: 15/34 (44%) (P < .0001 for all
comparisons to placebo). The majority of CD4+ (75%)
and CD8+ (60%) responses were directed towards
Gag253–284. CD8+ responses against Nef, Pol were
noted in 36% and 33% of vaccinees, respectively. At week
48, CD8+ responses persisted in 47/91 (52%) HIV-LIPO-
5 recipients.
Conclusion
ANRS VAC18 shows that low and high doses of HIV-
LIPO-5 vaccine elicit sustained CD8+ and CD4+ T-cell
responses. According to the good tolerance of the vaccine,
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the lowest dose of 50 μg appears as the most appropriate
to be used in further trials.